Author/Authors :
Chaudhary، نويسنده , , Amit and Hilton، نويسنده , , Mary Beth and Seaman، نويسنده , , Steven and Haines، نويسنده , , Diana C. and Stevenson، نويسنده , , Susan and Lemotte، نويسنده , , Peter K. and Tschantz، نويسنده , , William R. and Zhang، نويسنده , , Xiaoyan M. and Saha، نويسنده , , Saurabh and Fleming، نويسنده , , Tony and St. Croix، نويسنده , , Brad، نويسنده ,
Abstract :
Summary
t antiangiogenic agents used to treat cancer only partially inhibit neovascularization and cause normal tissue toxicities, fueling the need to identify therapeutic agents that are more selective for pathological angiogenesis. Tumor endothelial marker 8 (TEM8), also known as anthrax toxin receptor 1 (ANTXR1), is a highly conserved cell-surface protein overexpressed on tumor-infiltrating vasculature. Here we show that genetic disruption of Tem8 results in impaired growth of human tumor xenografts of diverse origin including melanoma, breast, colon, and lung cancer. Furthermore, antibodies developed against the TEM8 extracellular domain blocked anthrax intoxication, inhibited tumor-induced angiogenesis, displayed broad antitumor activity, and augmented the activity of clinically approved anticancer agents without added toxicity. Thus, TEM8 targeting may allow selective inhibition of pathological angiogenesis.
